East Bay cancer drug developer targets $100 million IPO By: San Francisco Business Times via Business Journals February 16, 2018 at 17:48 PM EST Backed by GV, The Column Group, Celgene and others, this cancer drug developer already has more than 80 people on staff. Read More >>
